Eyenovia (NASDAQ:EYEN) Receives “Hold” Rating from Brookline Capital Management

Brookline Capital Management reissued their hold rating on shares of Eyenovia (NASDAQ:EYEN) in a report published on Friday morning,Benzinga reports.

Several other research analysts also recently commented on EYEN. William Blair reissued a “market perform” rating on shares of Eyenovia in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eyenovia in a report on Wednesday.

Eyenovia Price Performance

EYEN traded down $0.24 on Friday, reaching $0.10. The company had a trading volume of 52,800,047 shares, compared to its average volume of 1,445,945. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.27 and a current ratio of 0.74. Eyenovia has a 52-week low of $0.09 and a 52-week high of $2.57. The company has a market cap of $6.53 million, a price-to-earnings ratio of -0.14 and a beta of 1.75. The business has a 50 day simple moving average of $0.49 and a 200 day simple moving average of $0.71.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period last year, the firm earned ($0.18) earnings per share. As a group, sell-side analysts anticipate that Eyenovia will post -0.56 EPS for the current year.

Insider Buying and Selling

In other news, CEO Michael M. Rowe purchased 50,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the transaction, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This represents a 151.85 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eyenovia

Hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eyenovia in the second quarter worth about $26,000. Ground Swell Capital LLC bought a new stake in shares of Eyenovia in the 2nd quarter worth approximately $27,000. Nations Financial Group Inc. IA ADV increased its stake in shares of Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares during the period. Financial Management Network Inc. bought a new position in shares of Eyenovia during the third quarter valued at approximately $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in Eyenovia in the second quarter worth $87,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.